The present invention relates to a Bicycle toxin conjugate BT5528, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof.

The present invention provides ophthalmic pharmaceutical compositions of the compound of Formula (I).

##STR(I)##

The present invention provides ophthalmic pharmaceutical compositions of the compound of Formula (I).

##STR(I)##

Disclosed herein is pharmaceutical compositions of Compound 1, and/or the hydroquinone form thereof, and methods useful for treating or suppressing a disease or disorder such as an α-synucleinpathy, a tauopathy, an autistic spectrum disorder, a pervasive developmental disorder, a liver disease, and liver damage in a subject using such pharmaceutical compositions.

A method of preparing a Polygoni Milletii Rhizome tincture includes: preparing a first mixture; extracting the first mixture with 70-90% ethanol under reflux condition to obtain a first extract solution; preparing a second mixture; extracting the second mixture with 50-70% ethanol to obtain a second extract solution; and mixing the first extract solution with the second extract solution to obtain the polygoni milletii rhizome tincture. A method of preparing a Polygoni Milletii Rhizome poultice includes: reparing a Polygoni Milletii Rhizome mixture; mixing the Polygoni Milletii Rhizome mixture and a skin penetration enhancer in water; mixing a moisturizing agent and a binder in water; adding a thickener in water; mixing methylparaben and ethylparaben in 90% ethanol; mixing all solutions to form a mixture; and applying the mixture on a non-woven fabric cloth and drying to form the Polygoni Milletii Rhizome poultice.

A method of preparing a Polygoni Milletii Rhizome tincture includes: preparing a first mixture; extracting the first mixture with 70-90% ethanol under reflux condition to obtain a first extract solution; preparing a second mixture; extracting the second mixture with 50-70% ethanol to obtain a second extract solution; and mixing the first extract solution with the second extract solution to obtain the polygoni milletii rhizome tincture. A method of preparing a Polygoni Milletii Rhizome poultice includes: reparing a Polygoni Milletii Rhizome mixture; mixing the Polygoni Milletii Rhizome mixture and a skin penetration enhancer in water; mixing a moisturizing agent and a binder in water; adding a thickener in water; mixing methylparaben and ethylparaben in 90% ethanol; mixing all solutions to form a mixture; and applying the mixture on a non-woven fabric cloth and drying to form the Polygoni Milletii Rhizome poultice.

The disclosure is directed to an oral formulation and dosage form of ruxolitinib, or a pharmaceutically acceptable salt thereof; which are useful in the treatment of Janus kinase (JAK) associated diseases.

The disclosure is directed to an oral formulation and dosage form of ruxolitinib, or a pharmaceutically acceptable salt thereof; which are useful in the treatment of Janus kinase (JAK) associated diseases.

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.